vs
INTEST CORP（INTT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
INTEST CORP的季度营收约是REGENXBIO Inc.的1.1倍（$32.8M vs $30.3M），INTEST CORP净利率更高（3.8% vs -221.3%，领先225.1%），REGENXBIO Inc.同比增速更快（43.0% vs -10.3%），INTEST CORP自由现金流更多（$-1.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.9%）
INTEST CORP是面向全球半导体产业的专业测试设备供应商，主营研发、生产及销售热管理系统、测试接口硬件、晶圆处理工具等产品，客户覆盖晶圆制造厂、芯片设计企业及汽车、工业电子等下游领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
INTT vs RGNX — 直观对比
营收规模更大
INTT
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出53.3%
-10.3%
净利率更高
INTT
高出225.1%
-221.3%
自由现金流更多
INTT
多$51.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.8M | $30.3M |
| 净利润 | $1.2M | $-67.1M |
| 毛利率 | 45.4% | — |
| 营业利润率 | 3.9% | -190.0% |
| 净利率 | 3.8% | -221.3% |
| 营收同比 | -10.3% | 43.0% |
| 净利润同比 | -17.4% | -31.2% |
| 每股收益（稀释后） | $0.10 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INTTRGNX
| Q4 25 | $32.8M | $30.3M | ||
| Q3 25 | $26.2M | $29.7M | ||
| Q2 25 | $28.1M | $21.4M | ||
| Q1 25 | $26.6M | $89.0M | ||
| Q4 24 | $36.6M | $21.2M | ||
| Q3 24 | $30.3M | $24.2M | ||
| Q2 24 | $34.0M | $22.3M | ||
| Q1 24 | $29.8M | $15.6M |
净利润INTTRGNX
| Q4 25 | $1.2M | $-67.1M | ||
| Q3 25 | $-938.0K | $-61.9M | ||
| Q2 25 | $-503.0K | $-70.9M | ||
| Q1 25 | $-2.3M | $6.1M | ||
| Q4 24 | $1.5M | $-51.2M | ||
| Q3 24 | $495.0K | $-59.6M | ||
| Q2 24 | $230.0K | $-53.0M | ||
| Q1 24 | $662.0K | $-63.3M |
毛利率INTTRGNX
| Q4 25 | 45.4% | — | ||
| Q3 25 | 41.9% | — | ||
| Q2 25 | 42.6% | — | ||
| Q1 25 | 41.5% | — | ||
| Q4 24 | 39.7% | 70.2% | ||
| Q3 24 | 46.3% | 48.8% | ||
| Q2 24 | 40.6% | 52.5% | ||
| Q1 24 | 43.8% | 72.6% |
营业利润率INTTRGNX
| Q4 25 | 3.9% | -190.0% | ||
| Q3 25 | -4.5% | -176.3% | ||
| Q2 25 | -3.3% | -296.3% | ||
| Q1 25 | -10.8% | 13.6% | ||
| Q4 24 | 5.7% | -242.1% | ||
| Q3 24 | 1.6% | -256.6% | ||
| Q2 24 | 1.0% | -251.3% | ||
| Q1 24 | 1.6% | -408.8% |
净利率INTTRGNX
| Q4 25 | 3.8% | -221.3% | ||
| Q3 25 | -3.6% | -208.3% | ||
| Q2 25 | -1.8% | -331.8% | ||
| Q1 25 | -8.7% | 6.8% | ||
| Q4 24 | 4.1% | -241.3% | ||
| Q3 24 | 1.6% | -246.3% | ||
| Q2 24 | 0.7% | -237.7% | ||
| Q1 24 | 2.2% | -405.4% |
每股收益（稀释后）INTTRGNX
| Q4 25 | $0.10 | $-1.30 | ||
| Q3 25 | $-0.08 | $-1.20 | ||
| Q2 25 | $-0.04 | $-1.38 | ||
| Q1 25 | $-0.19 | $0.12 | ||
| Q4 24 | $0.13 | $-0.99 | ||
| Q3 24 | $0.04 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $0.05 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.6M | $102.7M |
| 总资产 | $151.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INTTRGNX
| Q4 25 | $14.2M | $230.1M | ||
| Q3 25 | $16.2M | $274.2M | ||
| Q2 25 | $19.2M | $323.3M | ||
| Q1 25 | $22.0M | $267.9M | ||
| Q4 24 | $19.8M | $234.7M | ||
| Q3 24 | $18.0M | $255.5M | ||
| Q2 24 | $20.4M | $290.4M | ||
| Q1 24 | $27.3M | $338.7M |
总债务INTTRGNX
| Q4 25 | — | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $6.9M | — | ||
| Q4 24 | $7.9M | — | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $11.0M | — |
股东权益INTTRGNX
| Q4 25 | $103.6M | $102.7M | ||
| Q3 25 | $101.9M | $161.5M | ||
| Q2 25 | $102.6M | $213.7M | ||
| Q1 25 | $99.4M | $274.2M | ||
| Q4 24 | $99.8M | $259.7M | ||
| Q3 24 | $100.4M | $301.4M | ||
| Q2 24 | $99.5M | $348.3M | ||
| Q1 24 | $99.3M | $390.7M |
总资产INTTRGNX
| Q4 25 | $151.3M | $453.0M | ||
| Q3 25 | $148.3M | $525.2M | ||
| Q2 25 | $149.7M | $581.0M | ||
| Q1 25 | $148.0M | $490.9M | ||
| Q4 24 | $152.3M | $466.0M | ||
| Q3 24 | $158.4M | $519.1M | ||
| Q2 24 | $160.6M | $569.4M | ||
| Q1 24 | $159.5M | $629.2M |
负债/权益比INTTRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | 0.10× | — | ||
| Q1 24 | 0.11× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | -4.7% | -174.0% |
| 资本支出强度资本支出/营收 | 1.6% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.82× | — |
| 过去12个月自由现金流最近4个季度 | $5.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流INTTRGNX
| Q4 25 | $-1.0M | $-52.3M | ||
| Q3 25 | $3.5M | $-56.0M | ||
| Q2 25 | $-688.0K | $-49.3M | ||
| Q1 25 | $5.5M | $33.6M | ||
| Q4 24 | $2.6M | $-31.6M | ||
| Q3 24 | $4.2M | $-40.5M | ||
| Q2 24 | $-5.1M | $-45.5M | ||
| Q1 24 | $2.1M | $-55.5M |
自由现金流INTTRGNX
| Q4 25 | $-1.6M | $-52.8M | ||
| Q3 25 | $3.1M | $-56.5M | ||
| Q2 25 | $-1.1M | $-49.7M | ||
| Q1 25 | $5.3M | $32.6M | ||
| Q4 24 | $2.4M | $-32.7M | ||
| Q3 24 | $3.7M | $-40.9M | ||
| Q2 24 | $-5.4M | $-46.0M | ||
| Q1 24 | $1.7M | $-56.0M |
自由现金流率INTTRGNX
| Q4 25 | -4.7% | -174.0% | ||
| Q3 25 | 11.8% | -189.9% | ||
| Q2 25 | -4.1% | -232.8% | ||
| Q1 25 | 19.9% | 36.6% | ||
| Q4 24 | 6.6% | -154.2% | ||
| Q3 24 | 12.4% | -168.9% | ||
| Q2 24 | -15.9% | -206.2% | ||
| Q1 24 | 5.8% | -358.5% |
资本支出强度INTTRGNX
| Q4 25 | 1.6% | 1.7% | ||
| Q3 25 | 1.6% | 1.7% | ||
| Q2 25 | 1.6% | 1.8% | ||
| Q1 25 | 0.9% | 1.2% | ||
| Q4 24 | 0.4% | 5.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 1.1% | 3.6% |
现金转化率INTTRGNX
| Q4 25 | -0.82× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 1.72× | — | ||
| Q3 24 | 8.58× | — | ||
| Q2 24 | -22.13× | — | ||
| Q1 24 | 3.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INTT
| Environmental Technologies | $8.3M | 25% |
| Semiconductor Market | $6.9M | 21% |
| Thermal Testing Products | $6.4M | 19% |
| Service And Other Products | $4.8M | 15% |
| Oem Integrators And Distributor | $3.5M | 11% |
| Semiconductor Production Test Products | $3.0M | 9% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
